Send us Feedback

Home Diagnostics (HDIX)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

HDIX » Topics » Goodwill

These excerpts taken from the HDIX 10-K filed Mar 12, 2009.
Goodwill
 
Goodwill represents the excess of the purchase price over the fair value of assets acquired net of liabilities assumed in a purchase business combination. The Company periodically evaluates the acquisition of its businesses for potential impairment indicators. The Company’s judgments regarding the existence of impairment indicators are based on legal factors, market conditions and the operational performance of its business. The Company does not amortize goodwill, but rather tests goodwill for impairment at least annually, unless an event occurs which triggers the need for an earlier review. In accordance with SFAS No. 142, Goodwill and Other Intangible Assets, the Company tested goodwill for impairment by comparing the fair


50

Table of Contents

 
HOME DIAGNOSTICS, INC. AND SUBSIDIARIES
 
Notes to Consolidated Financial Statements — (Continued)
 
value of the reporting unit with its carrying amount, including goodwill. In determining the fair value, the Company utilized discounted future cash flows. Significant estimates used in the fair value calculation utilizing discounted future cash flows include, but are not limited to: (i) estimates of future revenue and expense growth; (ii) estimated average cost of capital; and (iii) the future terminal value of our reporting unit, which is based upon its ability to exist into perpetuity. The test for goodwill impairment requires significant estimates and judgment about future performance, cash flows and fair value. The Company’s future results could be affected if its estimates of future performance and fair value change. Any resulting impairment loss could have a material adverse impact on the Company’s financial condition and results of operations. The Company completed its annual test at December 31, 2007 and 2008, utilizing a discounted cash flow analysis and no impairment was identified as a result of this test.
 
Goodwill
 
Goodwill represents the excess of the purchase price over the fair value of assets acquired net of liabilities assumed in a purchase business combination. The Company periodically evaluates the acquisition of its businesses for potential impairment indicators. The Company’s judgments regarding the existence of impairment indicators are based on legal factors, market conditions and the operational performance of its business. The Company does not amortize goodwill, but rather tests goodwill for impairment at least annually, unless an event occurs which triggers the need for an earlier review. In accordance with SFAS No. 142, Goodwill and Other Intangible Assets, the Company tested goodwill for impairment by comparing the fair


50

Table of Contents

 
HOME DIAGNOSTICS, INC. AND SUBSIDIARIES
 
Notes to Consolidated Financial Statements — (Continued)
 
value of the reporting unit with its carrying amount, including goodwill. In determining the fair value, the Company utilized discounted future cash flows. Significant estimates used in the fair value calculation utilizing discounted future cash flows include, but are not limited to: (i) estimates of future revenue and expense growth; (ii) estimated average cost of capital; and (iii) the future terminal value of our reporting unit, which is based upon its ability to exist into perpetuity. The test for goodwill impairment requires significant estimates and judgment about future performance, cash flows and fair value. The Company’s future results could be affected if its estimates of future performance and fair value change. Any resulting impairment loss could have a material adverse impact on the Company’s financial condition and results of operations. The Company completed its annual test at December 31, 2007 and 2008, utilizing a discounted cash flow analysis and no impairment was identified as a result of this test.
 
Goodwill
 
Goodwill represents the excess of the purchase price over the fair value of assets acquired net of liabilities assumed in a purchase business combination. The Company periodically evaluates the acquisition of its businesses for potential impairment indicators. The Company’s judgments regarding the existence of impairment indicators are based on legal factors, market conditions and the operational performance of its business. The Company does not amortize goodwill, but rather tests goodwill for impairment at least annually, unless an event occurs which triggers the need for an earlier review. In accordance with SFAS No. 142, Goodwill and Other Intangible Assets, the Company tested goodwill for impairment by comparing the fair


50

Table of Contents

 
HOME DIAGNOSTICS, INC. AND SUBSIDIARIES
 
Notes to Consolidated Financial Statements — (Continued)
 
value of the reporting unit with its carrying amount, including goodwill. In determining the fair value, the Company utilized discounted future cash flows. Significant estimates used in the fair value calculation utilizing discounted future cash flows include, but are not limited to: (i) estimates of future revenue and expense growth; (ii) estimated average cost of capital; and (iii) the future terminal value of our reporting unit, which is based upon its ability to exist into perpetuity. The test for goodwill impairment requires significant estimates and judgment about future performance, cash flows and fair value. The Company’s future results could be affected if its estimates of future performance and fair value change. Any resulting impairment loss could have a material adverse impact on the Company’s financial condition and results of operations. The Company completed its annual test at December 31, 2007 and 2008, utilizing a discounted cash flow analysis and no impairment was identified as a result of this test.
 
Goodwill


 



Goodwill represents the excess of the purchase price over the
fair value of assets acquired net of liabilities assumed in a
purchase business combination. The Company periodically
evaluates the acquisition of its businesses for potential
impairment indicators. The Company’s judgments regarding
the existence of impairment indicators are based on legal
factors, market conditions and the operational performance of
its business. The Company does not amortize goodwill, but rather
tests goodwill for impairment at least annually, unless an event
occurs which triggers the need for an earlier review. In
accordance with SFAS No. 142, Goodwill and Other
Intangible Assets, the Company tested goodwill for impairment by
comparing the fair





50




Table of Contents





 




HOME
DIAGNOSTICS, INC. AND SUBSIDIARIES




 




Notes to
Consolidated Financial
Statements — (Continued)

 



value of the reporting unit with its carrying amount, including
goodwill. In determining the fair value, the Company utilized
discounted future cash flows. Significant estimates used in the
fair value calculation utilizing discounted future cash flows
include, but are not limited to: (i) estimates of future
revenue and expense growth; (ii) estimated average cost of
capital; and (iii) the future terminal value of our
reporting unit, which is based upon its ability to exist into
perpetuity. The test for goodwill impairment requires
significant estimates and judgment about future performance,
cash flows and fair value. The Company’s future results
could be affected if its estimates of future performance and
fair value change. Any resulting impairment loss could have a
material adverse impact on the Company’s financial
condition and results of operations. The Company completed its
annual test at December 31, 2007 and 2008, utilizing a
discounted cash flow analysis and no impairment was identified
as a result of this test.


 




Goodwill


 



Goodwill represents the excess of the purchase price over the
fair value of assets acquired net of liabilities assumed in a
purchase business combination. The Company periodically
evaluates the acquisition of its businesses for potential
impairment indicators. The Company’s judgments regarding
the existence of impairment indicators are based on legal
factors, market conditions and the operational performance of
its business. The Company does not amortize goodwill, but rather
tests goodwill for impairment at least annually, unless an event
occurs which triggers the need for an earlier review. In
accordance with SFAS No. 142, Goodwill and Other
Intangible Assets, the Company tested goodwill for impairment by
comparing the fair





50




Table of Contents





 




HOME
DIAGNOSTICS, INC. AND SUBSIDIARIES




 




Notes to
Consolidated Financial
Statements — (Continued)

 



value of the reporting unit with its carrying amount, including
goodwill. In determining the fair value, the Company utilized
discounted future cash flows. Significant estimates used in the
fair value calculation utilizing discounted future cash flows
include, but are not limited to: (i) estimates of future
revenue and expense growth; (ii) estimated average cost of
capital; and (iii) the future terminal value of our
reporting unit, which is based upon its ability to exist into
perpetuity. The test for goodwill impairment requires
significant estimates and judgment about future performance,
cash flows and fair value. The Company’s future results
could be affected if its estimates of future performance and
fair value change. Any resulting impairment loss could have a
material adverse impact on the Company’s financial
condition and results of operations. The Company completed its
annual test at December 31, 2007 and 2008, utilizing a
discounted cash flow analysis and no impairment was identified
as a result of this test.


 




Goodwill


 



Goodwill represents the excess of the purchase price over the
fair value of assets acquired net of liabilities assumed in a
purchase business combination. The Company periodically
evaluates the acquisition of its businesses for potential
impairment indicators. The Company’s judgments regarding
the existence of impairment indicators are based on legal
factors, market conditions and the operational performance of
its business. The Company does not amortize goodwill, but rather
tests goodwill for impairment at least annually, unless an event
occurs which triggers the need for an earlier review. In
accordance with SFAS No. 142, Goodwill and Other
Intangible Assets, the Company tested goodwill for impairment by
comparing the fair





50




Table of Contents





 




HOME
DIAGNOSTICS, INC. AND SUBSIDIARIES




 




Notes to
Consolidated Financial
Statements — (Continued)

 



value of the reporting unit with its carrying amount, including
goodwill. In determining the fair value, the Company utilized
discounted future cash flows. Significant estimates used in the
fair value calculation utilizing discounted future cash flows
include, but are not limited to: (i) estimates of future
revenue and expense growth; (ii) estimated average cost of
capital; and (iii) the future terminal value of our
reporting unit, which is based upon its ability to exist into
perpetuity. The test for goodwill impairment requires
significant estimates and judgment about future performance,
cash flows and fair value. The Company’s future results
could be affected if its estimates of future performance and
fair value change. Any resulting impairment loss could have a
material adverse impact on the Company’s financial
condition and results of operations. The Company completed its
annual test at December 31, 2007 and 2008, utilizing a
discounted cash flow analysis and no impairment was identified
as a result of this test.


 




These excerpts taken from the HDIX 10-K filed Mar 17, 2008.
Goodwill
 
Goodwill represents the excess of the purchase price over the fair value of assets acquired net of liabilities assumed in a purchase business combination. The Company periodically evaluates goodwill for potential impairment indicators. The Company’s judgments regarding the existence of impairment indicators are based on legal factors, market conditions and the operational performance of our business. The Company does not amortize goodwill, but rather tests goodwill for impairment at least annually, unless an event occurs which triggers the need for an earlier review. In accordance with SFAS No. 142, Goodwill and Other Intangible Assets, the Company tested goodwill for impairment by comparing the fair value of the reporting unit with its carrying amount, including goodwill. In determining the fair value, the Company utilized discounted future cash flows. Significant estimates used in the fair value calculation utilizing discounted future cash flows include, but are not limited to: (i) estimates of future revenue and expense growth; (ii) estimated average cost of capital; and (iii) the future terminal value of our reporting unit, which is based upon its ability to exist into perpetuity. The test for goodwill impairment requires significant estimates and judgment about future performance, cash flows and fair value. The Company’s future results could be affected if its estimates of future performance and fair value change. Any resulting impairment loss could have a material adverse impact on the Company’s financial condition and results of operations. The Company completed its annual test at December 31, 2006 and 2007, utilizing a discounted cash flow analysis and no impairment was identified as a result of this test.


52

Table of Contents

 
HOME DIAGNOSTICS, INC. AND SUBSIDIARIES
 
Notes to Consolidated Financial Statements — (Continued)
 
Goodwill


 



Goodwill represents the excess of the purchase price over the
fair value of assets acquired net of liabilities assumed in a
purchase business combination. The Company periodically
evaluates goodwill for potential impairment indicators. The
Company’s judgments regarding the existence of impairment
indicators are based on legal factors, market conditions and the
operational performance of our business. The Company does not
amortize goodwill, but rather tests goodwill for impairment at
least annually, unless an event occurs which triggers the need
for an earlier review. In accordance with
SFAS No. 142, Goodwill and Other Intangible Assets,
the Company tested goodwill for impairment by comparing the fair
value of the reporting unit with its carrying amount, including
goodwill. In determining the fair value, the Company utilized
discounted future cash flows. Significant estimates used in the
fair value calculation utilizing discounted future cash flows
include, but are not limited to: (i) estimates of future
revenue and expense growth; (ii) estimated average cost of
capital; and (iii) the future terminal value of our
reporting unit, which is based upon its ability to exist into
perpetuity. The test for goodwill impairment requires
significant estimates and judgment about future performance,
cash flows and fair value. The Company’s future results
could be affected if its estimates of future performance and
fair value change. Any resulting impairment loss could have a
material adverse impact on the Company’s financial
condition and results of operations. The Company completed its
annual test at December 31, 2006 and 2007, utilizing a
discounted cash flow analysis and no impairment was identified
as a result of this test.





52




Table of Contents





 




HOME
DIAGNOSTICS, INC. AND SUBSIDIARIES




 




Notes to
Consolidated Financial Statements —
(Continued)

 




EXCERPTS ON THIS PAGE:

10-K (6 sections)
Mar 12, 2009
10-K (2 sections)
Mar 17, 2008

RELATED TOPICS for HDIX:

"Goodwill" elsewhere:

ABIOMED (ABMD)
Antares Pharma (AIS)
MGC DIAGNOSTICS Corp (ANGN)
Alphatec Holdings (ATEC)
COMMERCE BANCORP INC (BJCT)
Cooper Companies (COO)
Conceptus (CPTS)
Haemonetics (HAE)
Kensey Nash (KNSY)
LeMaitre Vascular (LMAT)
Mesa Laboratories (MLAB)
Memry (MRY)
Pro-Dex (PDEX)
SonoSite (SONO)
Teleflex (TFX)
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki